At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 32 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic Profile and CNS Effects of BIA 2-093, in Young Healthy Male Volunteers.
In Brief
A Phase 1 clinical trial evaluating Placebo and BIA 2-093 for Epilepsy. Completed, enrolled 32 participants across 1 site.
Detailed Summary
The purpose of this study is to investigate the safety and tolerability of multiple dose regimens of BIA 2-093 in healthy young male volunteers
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 1CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2001
Primary CompletionJun 2001
First PostedJun 2014
TodayJul 2026
First PostedJun 24, 2014
Enrollment StartFeb 1, 2001
Primary CompletionJun 1, 2001
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 12.0 years ago
Interventions
Placebodrug
BIA 2-093drug